News / Taiwan / cnyes
Apex Medical Expects Strong H2 Growth, Targeting 20% Annual Rise in Overseas Markets
Health Technology · Medical Specialties · cnyes · 2026-08-26
6918
Orthopedic medical device manufacturer Apex Medical (6918) projects a stronger second half of the year, driven by international expansion and new product launches.
What Happened
Operational Outlook: Apex Medical (6918-TW) CEO Luo Xiang-wei stated that with the expansion of domestic product lines and the maturation of overseas strategies, the company expects second-half performance to surpass the first half, with H2 revenue accounting for over 50% of the annual total.
International Expansion: The company is actively penetrating Southeast Asian markets such as Singapore, Malaysia, Thailand, and Vietnam, while also exploring entry into Japan and Indonesia, aiming for a 20% annual growth rate in overseas revenue over the next few years.
China Market Strategy: In response to China's centralized procurement policies, Apex has shifted its product mix, with non-centralized procurement items now accounting for 70% of its Chinese revenue, led by strong sales of bunion correction and carbon fiber bone plate products.
Strategic Partnerships: Apex is currently in discussions with Japanese distributors regarding potential OEM collaborations, with further meetings scheduled for September, which could serve as a significant catalyst for the company's international growth.